BIT Capital GmbH Has $7.54 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BIT Capital GmbH grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 274,915 shares of the company's stock after purchasing an additional 52,494 shares during the period. BridgeBio Pharma comprises about 0.6% of BIT Capital GmbH's holdings, making the stock its 25th biggest holding. BIT Capital GmbH owned 0.15% of BridgeBio Pharma worth $7,544,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC boosted its stake in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after buying an additional 472 shares during the period. Advisors Asset Management Inc. grew its stake in BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after purchasing an additional 1,645 shares in the last quarter. Avanza Fonder AB acquired a new position in BridgeBio Pharma in the 4th quarter worth about $181,000. First Bank & Trust purchased a new stake in shares of BridgeBio Pharma during the 4th quarter worth about $205,000. Finally, Moss Adams Wealth Advisors LLC acquired a new stake in shares of BridgeBio Pharma during the 4th quarter valued at about $208,000. Hedge funds and other institutional investors own 99.85% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. Scotiabank increased their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Citigroup lifted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $52.64.

Remove Ads

BridgeBio Pharma Stock Down 1.6 %

Shares of NASDAQ:BBIO traded down $0.56 during mid-day trading on Monday, reaching $34.55. 841,355 shares of the stock were exchanged, compared to its average volume of 3,018,980. The stock's 50 day simple moving average is $34.26 and its 200-day simple moving average is $29.29. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The company has a market cap of $6.57 billion, a P/E ratio of -12.11 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. Analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 326,932 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28. Following the transaction, the chief executive officer now directly owns 5,371,515 shares of the company's stock, valued at $194,932,279.35. This represents a 5.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the transaction, the chief financial officer now directly owns 102,464 shares in the company, valued at approximately $3,705,098.24. This represents a 3.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,654,739 shares of company stock worth $325,937,151 in the last 90 days. Corporate insiders own 24.66% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.